Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lescol fluvastatin: Phase IV results; marketed to treat hypercholesterolemia, mixed dyslipidemia and atherosclerosis

Researchers published in JAMA previously reported results of a 4-year double-blind international

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE